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Abstract 
Obesity is a growing concern in the medical 
profession, particularly due to the co-morbidities 
that are related to obesity. Various methods have 
been trialled to manage obesity with varying 
effects, but can we ever say that one which is better 
than the other? This article looks at various 
lifestyle, pharmacological and surgical aspects of 
the management of obesity and discusses the 
diverse theories as to why the maintenance of 
weight loss can be difficult.  
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Obesity is defined as a medical condition in 
which excessive fat accumulation causes a negative 
impact on health.1 It is defined as a Body Mass 
Index equal or greater to 30. A sustained decrease 
of 10% initial body weight is effective in reducing 
co-morbidities.2 Current guidelines recommend a 
multi-disciplinary approach for obesity 
management.3-4 
Lifestyle approaches include dietary 
modification and/or exercise/activity prescription 
and behavioural therapy. Diets can result in 2.1-
6.6% weight loss.5 Lifestyle changes are a long-
term commitment and adherence to a diet plan is a 
big issue and one of the main causes that diets fail.6 
The addition of exercise to the dietary programs, 
significantly improve weight loss at follow up.7 
Behavioural therapy for obesity management is 
associated with an 8-10% weight loss. The issue 
with this intervention is that on discontinuation, the 
weight was noted to be regained.8 
The underlying assumption of lifestyle 
interventions implies that the patient has 
responsibility to maintain the weight loss. Mark 
(2006) challenges this view and introduces a 
proposition that the underlying increase in appetite 
arises as a direct result of weight loss.9 Liebel et 
al.’s study (1995)10 suggests that weight loss results 
in a decrease in total energy expenditure, explaining 
why weight loss maintenance is difficult. An 
alternative explanation could be secondary to the 
hormonal changes, such as leptin deficiency11 and 
ghrelin secretion, that occur during diet-induced 
weight loss.12 
Medication, such as Orlistat a reversible lipase 
inhibitor and Liragutide a glucagon-like peptide-1, 
have been used in the treatment of obesity.13-14 
Orlistat is the only medication approved in the 
paediatric age group.15 There is no doubt that anti-
obesity medication is more effective than placebo in 
inducing weight loss.16 However, this still only 
ranges between 0-7.6% weight loss.8 Moreover, 
morbidly obese patients are less likely to respond to 
pharmacotherapy.8 
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Bariatric surgery has resulted in effective 
weight loss in morbidly obese patients.17-18 This is 
namely offered to adults but recent trends show that 
it is also becoming a treatment option for 
adolescents.19 There are 3 main types of bariatric 
surgery procedures:  
1. Restrictive surgery: This involves a reduction
of the stomach size through gastric banding,
gastric sleeve or an intra-gastric balloon.
2. Malabsorptive surgeries: This involves re-
organisation of the digestive system which
impacts on its ability to absorb nutrients - e.g.
jejunoileal bypass, duodenal-jejunal bypass or
biliopancreatic division.
3. Combination Surgery: This involves a
combination of restrictive and malabsorptive
surgeries. Examples of this include Roux-en-
Y gastric bypass and biliopancreatic diversion
with duodenal switch.
One year on, the results of bariatric surgery 
are promising with 70 and 68% weight loss with 
biliopancreatic diversion and gastric bypass 
respectively and 48% weight loss following gastric 
banding.17 Sleeve gastrectomy and Roux-en-Y 
gastric bypass have better remission rates than those 
following gastric banding.20 Sleeve gastrectomy is a 
simpler procedure and is therefore easier to 
perform. It is associated with a reduced need of 
long-term post-operative multi-mineral and multi-
vitamin supplementation. If the target weight loss is 
not achieved, this procedure can be revised.20
 
Highest success in seen when such surgery is 
performed by a bariatric surgery specialist. 
Mortality risks and health care cost following 
bariatric surgery is promising. Mortality is reduced 
by 89%21 and health care costs are reduced by 29% 
at 5 years.22
 
This combined with the added 
advantages of the wholly or partial resolution of 
diabetes8 and improvement in the patient’s quality 
of life - rated at 95% improvement,23
 
places 
bariatric surgery as a valuable treatment option. 
Furthermore, long-term studies indicate sustained 
weight loss over 14 years, which is promising.24 
As with all treatments, there is a risk-benefit 
ratio that needs to be taken into account. Brethauer 
et al. (2006)8 phrases this succinctly: “the risks are 
not trivial, but they are acceptably low” (p. 993).  
Despite this, these must be explained and clarified 
to the person undergoing surgery in order to ensure 
that informed consent is achieved. The main 
surgical complications include bleeding, 
anastomotic leaks, wound infection, 
thromboembolism, anastomotic strictures, marginal 
ulcers, bowel obstruction and cholelitiasis. 
Nutritional deficiency (namely iron, calcium, 
Vitamin B12, Vitamin D) is another post-operative 
risk factor25 that can lead to secondary co-
morbidities such as secondary hyperparathyroidism. 
This can be managed by regular nutritional status 
levels and added supplementation.  
The core of obesity management is in a 
multidisciplinary approach and often one will find 
that a combination of treatment modalities are used. 
If obesity is considered as a chronic illness26 then a 
chronic disease model of care would be the most 
effective.  This would imply that each individual’s 
needs is assessed repeatedly throughout their care 
journey and a responsive care plan with the 
interventions tailored to the patients’ needs. 
Bariatric surgery provides far greater improvement 
in terms of immediate/long-term and co-morbidity 
outcomes, particularly in the treatment of morbid 
obesity4 and in those with diabetes.8,20,24 
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